Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy

Journal:

Nature Immunology

Published:

2026-01-16

DOI:

10.1038/s41590-025-02389-z

Affiliations:

7

Authors:

25

Go to article

Institutions	Authors	Share
University of Cambridge, United Kingdom (UK)	17.333333 17.333333	0.69
Peter MacCallum Cancer Centre (Peter Mac), Australia	3.500000	0.14
The University of Melbourne (UniMelb), Australia	1.500000	0.06
University of Dundee, United Kingdom (UK)	1.000000	0.04
Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER), France	1.000000	0.04
University of Oxford, United Kingdom (UK)	0.666667	0.03

Interested in Oncology and Carcinogenesis?